Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vistagen Therap. Com (VTGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 15,358
  • Shares Outstanding, K 8,580
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,220 K
  • 36-Month Beta N/A
  • Price/Sales 12.29
  • Price/Cash Flow N/A
  • Price/Book 5.95

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.75 +2.29%
on 05/26/17
2.40 -25.42%
on 05/01/17
-0.17 (-8.67%)
since 04/26/17
3-Month
1.74 +2.87%
on 03/27/17
2.75 -34.91%
on 02/28/17
-0.85 (-32.20%)
since 02/24/17
52-Week
1.74 +2.87%
on 03/27/17
4.69 -61.83%
on 09/23/16
-2.06 (-53.51%)
since 05/26/16

Most Recent Stories

More News
VistaGen Therapeutics' Largest Stockholder Signs 6-Month Lock-Up Agreement

SOUTH SAN FRANCISCO, CA--(Marketwired - May 01, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 1.79 (-2.19%)
VistaGen Therapeutics' Largest Stockholder Signs 6-Month Lock-Up Agreement

SOUTH SAN FRANCISCO, CA--(Marketwired - May 01, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 1.79 (-2.19%)
5 Drug Stocks for Your Portfolio this World Health Day

With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.

JNJ : 126.92 (-0.48%)
AGN : 223.12 (-0.55%)
SAGE : 66.04 (-3.10%)
ALKS : 57.70 (-0.41%)
VTGN : 1.79 (-2.19%)
VistaGen Therapeutics Receives European Patent Office Notice of Intention to Grant European Patent for AV-101

SOUTH SAN FRANCISCO, CA--(Marketwired - March 29, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 1.79 (-2.19%)
VistaGen Therapeutics Inc. (Nasdaq: VTGN) to Ring The Nasdaq Stock Market Closing Bell

What:

NDAQ : 67.58 (-0.89%)
VTGN : 1.79 (-2.19%)
VistaGen Therapeutics to Present at Biotech Showcase(TM) 2017

VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central nervous system (CNS) disorders, announced...

VTGN : 1.79 (-2.19%)
VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell Technologies to BlueRock Therapeutics

VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation therapies for depression and other central nervous system (CNS) disorders, today...

VTGN : 1.79 (-2.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Support & Resistance

2nd Resistance Point 1.88
1st Resistance Point 1.84
Last Price 1.79
1st Support Level 1.75
2nd Support Level 1.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.